Adze Biotechnology Completes $6.2 Million First Closing of Series A Financing
“This first close of our Series A furthers our mission of bringing potentially life-saving treatments to patients in need.” –
March 16, 2023
Adze Biotechnology Announces Orphan Drug Designation Granted to Adze-1.17-CD40L for the treatment of Malignant Glioma
CORAL GABLES, FLORIDA, UNITED STATES, February 7, 2023 Adze-1.17-CD40L is a systemically deliverable, conditionally replicative oncolytic virus that delivers recombinent
February 10, 2023
Adze Biotechnology Granted Patent for its Proprietary Oncolytic Adenovirus Platform
CORAL GABLES, FLORIDA, UNITED STATES, February 1, 2023. The grant of this patent positions Adze to participate in the $18
February 1, 2023